Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.47 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647959 | 1.00 | KDM1A (0.62) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL10148484 | 0.88 | EPHX2 (0.63) | KDM1AMAOBEPHX2FAAH | |
| SCHEMBL29973425 | 0.88 | EPHX2 (0.63) | KDM1AMAOBEPHX2FAAH | |
| SCHEMBL25060070 | 0.88 | EPHX2 (0.54) | KDM1AMAOBEPHX2FAAHDRD2 | |
| SCHEMBL30182719 | 0.87 | KDM1A (0.56) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL25136336 | 0.87 | KDM1A (0.56) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL31669351 | 0.86 | EPHX2 (0.55) | KDM1AMAOBEPHX2FAAHDRD2 | |
| SCHEMBL24011176 | 0.86 | KDM1A (0.50) | KDM1AMAOBEPHX2DRD2CKS1B | |
| SCHEMBL18615484 | 0.86 | KDM1A (0.50) | KDM1AMAOBEPHX2DRD2CKS1B | |
| SCHEMBL1412244 | 0.86 | ALDH1A1 (0.66) | KDM1AMAOBEPHX2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-09 | — | — | US | disclosed |
| CN-105801489-B | Cycloalkyl-substituted imidazole derivatives | 第一三共株式会社 | 2019-12-10 | — | — | CN | disclosed |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| WO-2017123542-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | WO | disclosed |
| EP-2548871-B1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9340531-B2 | Cycloalkyl-substituted imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-17 | — | — | US | disclosed |
| US-9340531-B2 | Cycloalkyl-substituted imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-17 | — | — | US | disclosed |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-05 | — | — | US | disclosed |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-05 | — | — | US | disclosed |
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2548871-A1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | KDM1A 1952/4885MAOB 2329/4885EPHX2 1644/4885 |
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | KDM1A 2872/4885MAOB 586/4885EPHX2 2856/4885 |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | AR, SHBG, NR5A1 | KDM1A 1952/4885MAOB 2329/4885EPHX2 1644/4885 |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | KDM1A 1952/4885MAOB 2329/4885EPHX2 1644/4885 |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | KDM1A 2872/4885MAOB 586/4885EPHX2 2856/4885 |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | KDM1A 1952/4885MAOB 2329/4885EPHX2 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.